コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 temness with higher angiogenic potential and tumorigenicity.
2 proteins BMI-1 and EZH2, which contribute to tumorigenicity.
3 eactivation of progenitor functions supports tumorigenicity.
4 a mechanism through which DAXX promotes PCa tumorigenicity.
5 in miR-21KD cancer cells restored their high tumorigenicity.
6 crophage ratios may account for the enhanced tumorigenicity.
7 th by coordinately linking immune escape and tumorigenicity.
8 nuated DCA-induced colorectal cancer or PDAC tumorigenicity.
9 latory promoter regions, leading to enhanced tumorigenicity.
10 n connection between CFIm25 and glioblastoma tumorigenicity.
11 a consequence of miR-9 inhibition, increases tumorigenicity.
12 , indicating regulation of proliferation and tumorigenicity.
13 creased cellular senescence, and/or enhanced tumorigenicity.
14 ssion of miR-9 upregulates FOXP1 to increase tumorigenicity.
15 induce gene expression programs essential in tumorigenicity.
16 miting oxygen conditions may be required for tumorigenicity.
17 whereas Prep1 overexpression inhibits Meis1 tumorigenicity.
18 by both altering the immunogenicity and the tumorigenicity.
19 ll growth, promigratory characteristics, and tumorigenicity.
20 tion and induced apoptosis but also impaired tumorigenicity.
21 cancer-specific epigenetic abnormalities on tumorigenicity.
22 to overexpress tissue factor increased their tumorigenicity.
23 n levels of RNAs and of their changes during tumorigenicity.
24 usly and demonstrates for the first time its tumorigenicity.
25 tissue factor did not increase their limited tumorigenicity.
26 gulator of stress responses, metabolism, and tumorigenicity.
27 e the epigenetic drivers causing the loss of tumorigenicity.
28 cers and its levels appear to correlate with tumorigenicity.
29 to increased rates of cell proliferation and tumorigenicity.
30 s, to further examine their oncogenicity and tumorigenicity.
31 terminally differentiated with abrogation of tumorigenicity.
32 thesis-that is important for prostate cancer tumorigenicity.
33 critical role of SALL4 in cell survival and tumorigenicity.
34 ompanied with loss of both proliferation and tumorigenicity.
35 nockdown of SNRK increased colon cancer cell tumorigenicity.
36 rs have been shown to be important for their tumorigenicity.
37 8 breast cancer cells and is associated with tumorigenicity.
38 e perivascular niches as well as in melanoma tumorigenicity.
39 breast cancer cell differentiation state and tumorigenicity.
40 progression whereas its inactivation reduced tumorigenicity.
41 es of cancer cells with different degrees of tumorigenicity.
42 ing an STF program associated with increased tumorigenicity.
43 s of hierarchical or differentiative loss of tumorigenicity.
44 significantly increased HER-2 expression and tumorigenicity.
45 red proliferation but increased intracranial tumorigenicity.
46 A methyltransferases for CSC maintenance and tumorigenicity.
47 an important modulator and even a driver of tumorigenicity.
48 in C receptor (EPCR) in MPM cells suppresses tumorigenicity.
49 stic phenotype and contributes to epithelial tumorigenicity.
50 perties, thyrosphere formation, and enhanced tumorigenicity.
51 ollutants in Caco-2 cells and increase their tumorigenicity.
52 ion ultimately contributing to LMW-E-induced tumorigenicity.
53 ssive properties of hMSC and increased their tumorigenicity.
54 reduced stem marker expression and decreased tumorigenicity.
56 ed serine protease encoded by suppression of tumorigenicity-14 (ST14) gene, which is critical for epi
57 ed serine protease encoded by Suppression of Tumorigenicity-14 (ST14) that strengthens the intestinal
58 al motifs [reck; also known as suppressor of tumorigenicity 15 protein (ST15)], which encodes a membr
60 c changes in IL33 and soluble suppression of tumorigenicity 2 (sST2) levels were measured in the plas
61 C motif) ligand 9 (CXCL9) and suppression of tumorigenicity 2 (ST2) also were measured on the basis o
62 the role of the IL-33 receptor suppressor of tumorigenicity 2 (ST2) in the persistence of asthma in a
65 acid-binding protein, soluble suppression of tumorigenicity 2, and lipopolysaccharide were assessed.
67 p < 0.0001) and day 3 soluble suppression of tumorigenicity-2 (median, 7,678 mL [interquartile range,
68 We assayed plasma soluble suppression of tumorigenicity-2 (n = 826) concentrations and interleuki
69 for reintubation for soluble suppression of tumorigenicity-2 (odds ratio, 3.23; 95% CI, 1.04-10.07;
72 ay 0 and day 3 median soluble suppression of tumorigenicity-2 and interleukin-6 concentrations had de
74 We determined whether soluble suppression of tumorigenicity-2 and interleukin-6 levels can be used as
75 We tested whether soluble suppression of tumorigenicity-2 and interleukin-6 levels were associate
76 , interleukin-33, and soluble suppression of tumorigenicity-2 between matched patients who were treat
77 anagement and whether soluble suppression of tumorigenicity-2 concentration discriminates acute respi
78 ermine whether plasma soluble suppression of tumorigenicity-2 concentration is associated with outcom
79 ty of illness, higher soluble suppression of tumorigenicity-2 concentration was associated with morta
85 nd interleukin-33 and soluble suppression of tumorigenicity-2) within 24 hours of acute respiratory d
86 75; p < 0.0001; day 3 soluble suppression of tumorigenicity-2: hazard ratio, 0.64; 95% CI, 0.54-0.75;
87 tion over time (day 0 soluble suppression of tumorigenicity-2: hazard ratio, 0.85; 95% CI, 0.72-1.00;
88 eous breathing trial (soluble suppression of tumorigenicity-2: odds ratio, 0.45; 95% CI, 0.28-0.71; p
89 weaning assessments (soluble suppression of tumorigenicity-2: odds ratio, 0.62: 95% CI, 0.44-0.87; p
90 opulation within neuroblastoma with enhanced tumorigenicity and a stem cell-like phenotype, further e
92 levels of GHCer displayed relatively greater tumorigenicity and angiogenesis compared with cells expr
93 stable, not consistently linked to increased tumorigenicity and associated with genetic heterogeneity
98 de mechanistic insight, we assessed relative tumorigenicity and differentiation potential via xenotra
99 OSIC-like properties of self-renewal, strong tumorigenicity and differentiation to CD49f(+) progeny.
101 e of the side population (SP) and in vivo as tumorigenicity and experimental metastatic potential in
102 Let-7 targets Imp1-3 are required for this tumorigenicity and feed back to reinforce and sustain ex
106 AID-mediated genomic damage led to altered tumorigenicity and indolent behavior of tumor cells in v
107 DLGAP5 silencing in cancer cells suppressed tumorigenicity and inhibited cellular proliferation by a
108 miR-124 and knockdown of SNAI2 inhibited the tumorigenicity and invasion of glioma cells in vivo.
109 ovel mechanism by which Vav1 can enhance the tumorigenicity and invasive potential of cancer cells.
111 sion of miR-141 is inversely correlated with tumorigenicity and invasiveness in several human cancers
112 indicate the importance of this pathway for tumorigenicity and invasiveness of KDM2A-overexpressing
114 biological relationships among self-renewal, tumorigenicity and lineage differentiation of human oste
116 Because N2P2 has been shown to increase tumorigenicity and M3P6 to decreases it, we sought to de
120 state cancer (PCa) cell migration, invasion, tumorigenicity and metastasis using a human PCa progress
126 riptase activity and significantly decreased tumorigenicity and metastatic capability in orthotopical
128 of the spliceosome in vivo impairs survival, tumorigenicity and metastatic proclivity of MYC-dependen
129 mary luminal differentiation, can reduce the tumorigenicity and metastatic propensity of the human BT
132 ls lacking DeltaEGFR potently enhanced their tumorigenicity and produced highly vascularized tumors,
133 ivated in TNBC and has a pivotal role in the tumorigenicity and progression of this human breast canc
134 n increased cell motility, invasiveness, and tumorigenicity and provides a valuable model for studyin
135 n hNCPCs(V600E) dramatically increased their tumorigenicity and resulted in fully transformed tumor c
138 B enhances the several phenotypes, including tumorigenicity and sphere-forming ability, which are ind
139 FGFR3 mutations have very limited urothelial tumorigenicity and that these mutations must collaborate
140 ays an integral role in enhancing pancreatic tumorigenicity and the function of cancer stem cells in
141 ay for in vivo evaluation of CTCL cell lines tumorigenicity and therapeutic response in preclinical s
142 ene-expression profiles that could influence tumorigenicity and therapeutic response, and we therefor
143 s, regulation of metastases genes, increased tumorigenicity and was important for BCSC invasion and m
144 ltaEGFR access to the nucleus attenuates its tumorigenicity and, conversely, that promoting nuclear a
145 sed in GSCs, play a key role in glioblastoma tumorigenicity, and are potential therapeutic targets ag
146 the long-term (>5 weeks) effects, potential tumorigenicity, and fate of transplanted CPCs are unknow
147 icate that PIM1 may be necessary to maintain tumorigenicity, and further support efforts aimed at dev
150 ifferences in self-renewal, gene expression, tumorigenicity, and metastatic potential of spheres at g
152 associated with increased EGFR activity and tumorigenicity, and we found that Rak/Frk associates pre
153 nisms by which Nkx3.1 loss promotes prostate tumorigenicity are not completely understood, published
154 pG2, the stable transformant showed enhanced tumorigenicity as evident by its sustained growth in low
155 lanoma-specific PD-1 overexpression enhances tumorigenicity, as does engagement of melanoma-PD-1 by i
158 ed a remarkable increase in self-renewal and tumorigenicity associated with long-lasting gene express
159 contrary to expectations, the mechanisms of tumorigenicity associated with mutations in different ge
160 ased tumorsphere formation ability, enhanced tumorigenicity both in vitro and in vivo and drug resist
161 y establishes that miR-221 can promote liver tumorigenicity, but it also establishes a valuable anima
162 G2 cells leads to enhanced cell survival and tumorigenicity by activating HA-mediated cell survival p
163 NG functions to drive transformed growth and tumorigenicity by activating PKCiota-dependent cell auto
164 atory network revealed that XBP1 drives TNBC tumorigenicity by assembling a transcriptional complex w
165 esults in an increased CSC-like property and tumorigenicity by enhancing the interaction of beta-cate
166 , this study shows that ILF3 promotes breast tumorigenicity by regulating sustained uPA expression.
167 , this study shows that ILF3 promotes breast tumorigenicity by regulating sustained uPA expression.On
168 iate into quasi-normal cells with suppressed tumorigenicity by selective inhibition of the MAPK/ERK/M
170 reatment to induce persistent attenuation of tumorigenicity by targeting tumor-initiating cells.
172 identify OSIC-like cells that possess strong tumorigenicity correlated with an impaired osteogenic fa
173 governs epithelial cell plasticity, EMT, and tumorigenicity during breast cancer initiation and progr
174 cells showed no signs of hyperproliferation, tumorigenicity, ectopic tissue formation, or apparent re
175 ced proliferation, apoptosis resistance, and tumorigenicity, effects rescued by estrogen supplementat
176 r proliferation, survival, Erk signaling and tumorigenicity even when MYC levels were not significant
178 D24, ALDH-1, EpCAM, Lgr5), multipotency, and tumorigenicity following injection in immunodeficient mi
179 en adapted for in vivo experiments and their tumorigenicity has not been adequately assessed, hamperi
182 carefully monitor for the potential risks of tumorigenicity, immunogenicity, and arrhythmogenicity.
183 r B (IL-17RB) and its ligand IL-17B promoted tumorigenicity in breast cancer cells and impeded acinus
186 STAT3 signaling, cell-cycle progression, and tumorigenicity in human colorectal cancer and pancreatic
192 cer stem cells in vitro, as well as enhanced tumorigenicity in murine models of primary tumour growth
196 l colonocytes was well correlated with colon tumorigenicity in our patient cohort and in an independe
197 , anchorage-independent growth in vitro, and tumorigenicity in severe combined immunodeficiency mice
200 orrelated with chemoresistance and increased tumorigenicity in vitro and in vivo accompanied by incre
203 educed cell proliferation, cell invasion and tumorigenicity in vitro, but also inhibited tumor growth
205 ion, and drug resistance in vitro and higher tumorigenicity in vivo than those constitutively express
206 endometrial cancer cell growth in vitro and tumorigenicity in vivo, as a result of inhibition of cel
207 ge-independent growth in vitro and restrains tumorigenicity in vivo, possibly through the control of
208 e adenocarcinoma-like histology in vitro and tumorigenicity in vivo, recapitulating multi-hit models
218 promotes malignant progression of HBECs and tumorigenicity, invasion, and metastases in non-small ce
219 phere-forming ability, and exhibit increased tumorigenicity, known characteristics of cancer stemness
220 FkappaB levels and ameliorate the growth and tumorigenicity, leading to improved clinical outcomes.
223 e importance of PAR1 to the self-renewal and tumorigenicity of A2B5-defined glioma TPCs; as such, the
224 of A549 lung cancer cells and suppresses the tumorigenicity of A549 cells in severe combined immunode
225 rotein alone, significantly enhances in vivo tumorigenicity of AGS gastric cancer cells and correlate
230 hermore, blocking RSPO signaling reduced the tumorigenicity of cancer cells based on serial transplan
231 ever, the molecular mechanisms promoting the tumorigenicity of cancer cells undergoing an EMT and of
235 transformed cells, we compared the relative tumorigenicity of Cre-LoxP conditional disruption of the
238 ntial treatment in a number of diseases, the tumorigenicity of embryonic stem cells (ESC) and induced
244 ombination with HER2 inhibitors, reduced the tumorigenicity of HR(-)/HER2(+) breast cancers, opening
245 t studies, we demonstrate that DAXX promotes tumorigenicity of human ALVA-31 and PC3 prostate cancer
246 inally, SIRT7 depletion markedly reduces the tumorigenicity of human cancer cell xenografts in mice.
250 IKBKE-associated cytokine signaling promotes tumorigenicity of immune-driven TNBC and identify a pote
252 lated ABCG2, and inhibited proliferation and tumorigenicity of lung and esophageal cancer cells.
253 N axis synergistically suppresses growth and tumorigenicity of lung cancer cells, our findings may op
254 culture and in soft agar and suppresses the tumorigenicity of MCF-7 cells in severe combined immunod
255 6 as key players for migration, invasion and tumorigenicity of melanoma cells, as integral subunits o
257 the processed product of p105), inhibits the tumorigenicity of NF-kappaB1-deficient lung tumor cells.
258 IKKalpha induces differentiation and reduces tumorigenicity of NPC cells without activating NF-kappaB
260 FGF18 controlled migration, invasion, and tumorigenicity of ovarian cancer cells through NF-kappaB
264 s, promoted radiosensitization, and hindered tumorigenicity of radioresistant prostate cancer cells.
265 pathway-regulated cofactor YAP1 supports the tumorigenicity of RAS mutations but requires both inacti
266 mately beta) inhibited the proliferation and tumorigenicity of Ras(V12)-transformed NIH 3T3 cells, ac
267 r transformation; however, the importance to tumorigenicity of RNA 3'-end-processing factors that pot
271 n vitro pancreatic cancer cell migration and tumorigenicity of the side population of pancreatic canc
274 er, the V777L mutation did not alter in vivo tumorigenicity or sensitivity to HER2-directed therapies
276 macroH2A1 in bladder cancer cells increased tumorigenicity, radioresistance, degeneration of reactiv
277 s (GSCs), whose viability, self-renewal, and tumorigenicity rely, at least in part, on signaling thro
279 to be ganglioside deficient exhibit impaired tumorigenicity, supporting a link between ganglioside-de
280 Those findings are here extended to in vivo tumorigenicity testing by employing orthotopic xenotrans
281 ESA(hi)PROCR(hi)SSEA-3(+) markers had higher tumorigenicity than those with conventional markers in v
282 12(R) had faster proliferation with stronger tumorigenicity that was caused by the reactivated KIT ki
284 and ChIP studies revealed that KDM2B drives tumorigenicity through 2 different transcriptional mecha
286 We here report that EMT confers efficient tumorigenicity to murine breast cancer cells by the upre
288 s deprived of nutrients but suppressed their tumorigenicity, together suggesting the cancer cells ent
290 promotes self-renewal, and then examined for tumorigenicity under limiting dilution conditions and cl
293 yed characteristics of OSFC: limited in vivo tumorigenicity, weak lineage differentiation, more diffe
294 h a significant growth delay and the loss of tumorigenicity when 10(4) cells were injected into mice.
296 RSPO2 suppresses CRC cell proliferation and tumorigenicity, whereas the depletion of RSPO2 enhances
297 cks its proteasomal destruction and enhances tumorigenicity, which could be reversed by Usp9x knockdo
298 h factor receptor) marks cells with enriched tumorigenicity, which would compel their specific target
299 to a striking inhibition of EGFRvIII-induced tumorigenicity, while increasing EGFRwt or HB-EGF levels
300 ived cancer cells, with simultaneous loss of tumorigenicity, without the need to revert to an embryon
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。